Vaccination against RSV: is maternal vaccination a good alternative to other approaches?

Area of Science:

• Virology
• Immunology
• Public Health

Background:

• Respiratory syncytial virus (RSV) is a leading cause of lower respiratory tract illness (LRI) globally, particularly in infants.
• Individuals with chronic heart/lung conditions, immunodeficiency disorders, and the elderly are also at high risk for severe RSV-associated LRI.
• Currently, no licensed RSV vaccine is available, making it a critical target for vaccine development.

Purpose of the Study:

• To discuss essential considerations for the successful integration of a new RSV vaccine into national immunization programs.
• To identify knowledge gaps requiring further research for effective RSV vaccine implementation.
• To evaluate different vaccination strategies, including maternal immunization, infant vaccination, and immunization of specific risk groups.

Main Methods:

• Review of existing knowledge on RSV disease pathology, epidemiology, and immunology.
• Analysis of factors influencing vaccine implementation, such as seasonality and maternal antibody interference.
• Evaluation of various immunization strategies tailored to different populations.

Main Results:

• Successful implementation requires addressing RSV disease seasonality and the infant immune system's immaturity.
• Maternal immunization presents a promising strategy, alongside direct infant vaccination and targeted immunization of high-risk groups.
• Understanding and mitigating the interference of maternal antibodies is crucial for vaccine efficacy.

Conclusions:

• Strategic planning, informed by RSV's biological and epidemiological characteristics, is vital for successful vaccine rollout.
• A multi-pronged approach, potentially combining maternal and infant vaccination, may be necessary to control RSV disease.
• Further research is needed to optimize vaccination schedules and address immunological challenges in infants and specific risk groups.